Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
API manufacturing finally getting the attention it deserves
While formulation generics flounders a bit, the data show that the Indian API industry has done better, with a five-year revenue…
Will FMRAI’s PIL finally prod govt to make UCPMP mandatory?
As COVID-19 continues to extract its price, will a more aware patient pool build up public opinion and turn the tide?
High expectations from the draft Bill
The regulation of all retail channels as proposed by the draft Drugs, Medical Devices and Cosmetics Bill 2022 becomes even more…
India’s medicine watchdog under the scanner once again
Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Preparing for surprise inspections
Will surprise site inspections be the end of a long wait? Or the start of another tunnel into noncompliance?
Taking India beyond ‘Pharmacy of the World’
A policy to incentivise pharma R&D is crucial as there are already signs that pharma R&D dives when revenues dip
Will a limited vaccine waiver limit future options?
As attempts to ring-fence markets and restrict access continue, will India and South Africa toe the WTO line?
Still tripping on TRIPS
If India, one of the main proponents of the TRIPS waiver, is left out, is it time for an ‘India waiver’ to show the way forward?
Filling the gaps in India’s pharma manufacturing supply chain
The lessons of the past – of spiralling API costs, overdependence on a shrinking list of API makers – have been well learnt